Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study
Not Applicable
Completed
- Conditions
- Coronary Artery Bypass Grafting
- Interventions
- Dietary Supplement: CurcuminoidsOther: Placebo
- Registration Number
- NCT01528514
- Lead Sponsor
- Wanwarang Wongcharoen, MD.
- Brief Summary
It is well-established that myocardial infarction (MI) associated with coronary artery bypass graft surgery (CABG) predicts the poor outcome. Nevertheless, the cardioprotective therapies to limit myocardial injury after CABG are lacking. Previous studies have shown that curcuminoids suppress pro-inflammatory cytokines during cardiopulmonary bypass surgery and decrease the occurrence of cardiomyocytic apoptosis after cardiac ischemia/reperfusion injury in animal models. The investigators aim to evaluate whether curcuminoids prevent MI after CABG, compared to placebo.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Patients undergoing CABG without valve surgery
Exclusion Criteria
- emergency cardiac surgery
- any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization
- patients with cholestatic jaundice (total bilirubin > 2-fold ULN)
- severe liver disease (AST or ALT > 3-fold ULN)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Curcuminoids Curcuminoids - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Incidence of postoperative myocardial infarction participants will be followed for the duration of hospital stay, an expected average of 10 days
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Maharaj Nakorn Chiang Mai hospital
🇹🇭Chiang Mai, Thailand